· IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 1 6 2002

In re the application of: Michael J. M.

Serial No.: 09/643,260

Filed: August 22, 2000

For: INHIBITION OF NF-κΒ ACTION BY BLOCKADE OF IKKβ-NEMO INTERACTIONS AT THE

NEMO BINDING DOMAIN

Attorney Docket No.: PPI-117

Commissioner for Patents Washington, D.C. 20231

Group Art Unit: 1653

Examiner: Mitra, Rita

TECH CENTER 1600/2900

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

By:

Date of Signature and of Mail Deposit

Maria C. Laccotripe, Ph.D.

Limited Recognition Under 37 C.F.R. §10.9(b)

Attorney for Applicant

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the Office Action dated June 10, 2002 (Paper No. 7) setting forth a restriction requirement.

The Examiner has required restriction to one of the following inventions under 35 U.S.C. §121:

I. Claims 1-5, drawn to a method of inhibiting NF-kB induction in a cell by administering a peptide which blocks the interaction of one or more IKKs and NEMO, classified in class 514, subclass 2.

Should Group I be elected, applicants are required to select one sequence of peptides of SEQ ID NOs:2, 4-6, 11-12, 16-17.